Newsroom

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了第三期MANGROVE研究(BGB-3111-306; NCT04002297)的正面初步主要結果。該研究評估了基礎性BTK抑制劑BRUKINSA® (zanubrutinib)聯合rituximab對比bendamustine聯合rituximab (BR)在既往未經治療的套細胞淋巴瘤(MCL)成人病患中的療效。MANGROVE是第一個在此類病患中評估以BTK抑制劑為基礎的無化療方案對比標準化療免疫療法的第三期全球性隨機試驗。這項關鍵的第三期試驗建立在BRUKINSA治療MCL的已有臨床證據基礎之上。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示： 「對於新診斷的MCL病患，化療目前是默認選擇。MANGROVE首次證明，BRUKINSA聯合rituximab這一無化療方案，能夠帶來前所未見的無惡化存活期改善，可望在全球重新定義治療...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), uma empresa global de oncologia, anunciou hoje resultados preliminares positivos do estudo de Fase 3 MANGROVE (BGB-3111-306; NCT04002297), que avalia o inibidor de BTK de referência BRUKINSA®(zanubrutinibe) associado ao rituximabe em comparação com bendamustina associada ao rituximabe (BR) em pacientes adultos com linfoma de células do manto (LCM) não tratado anteriormente. O MANGROVE é o pr...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société internationale spécialisée en oncologie, a annoncé aujourd’hui les les résultats préliminaires positifs de l’étude de phase III MANGROVE (BGB-3111-306 ; NCT04002297) évaluant BRUKINSA® (zanubrutinib), un inhibiteur de BTK servant de traitement de base, associé au rituximab par rapport à la bendamustine associée au rituximab (BR) chez des patients adultes atteints d’un lymphome à c...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa oncológica internacional, anunció hoy resultados preliminares positivos del estudio de fase 3 MANGROVE (BGB-3111-306; NCT04002297 ) que evalúa el inhibidor de la tirosina quinasa de Bruton como tratamiento base, BRUKINSA® (zanubrutinib), en combinación con rituximab, frente al tratamiento de bendamustina y rituximab en pacientes adultos con linfoma de células del manto (LCM) que no hab...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica globale, oggi ha annunciato i risultati iniziali positivi dallo studio di fase 3 MANGROVE (BGB-3111-306; NCT04002297) volto a valutare l'inibitore fondamentale della tirosin-chinasi di Bruton (BTK) BRUKINSA® (zanubrutinib) in combinazione con rituximab rispetto a bendamustine più rituximab (BR) nei pazienti adulti affetti da linfoma delle cellule mantellari (MCL) non preceden...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een bedrijf dat wereldwijd actief is op het gebied van oncologie, heeft vandaag positieve voorlopige resultaten bekendgemaakt van het fase 3-onderzoek MANGROVE (BGB-3111-306; NCT04002297. In de studie werd de toonaangevende BTK-remmer BRUKINSA® (zanubrutinib) in combinatie met rituximab vergeleken met bendamustine in combinatie met rituximab (BR) bij volwassen patiënten met niet eerder behandeld m...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute positive Topline-Ergebnisse aus der Phase-3-MANGROVE-Studie (BGB-3111-306; NCT04002297) bekannt, in der der grundlegende BTK-Inhibitor BRUKINSA® (Zanubrutinib) plus Rituximab im Vergleich zu Bendamustin plus Rituximab (BR) bei erwachsenen Patienten mit zuvor unbehandeltem Mantelzell-Lymphom (MCL) untersucht wird. MANGROVE ist die erste glob...

TOKYO--(BUSINESS WIRE)--NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491), a leading manufacturer of cold-rolled stainless steel, today introduced its new "Decorative Stainless Steel Finishes for Exterior Use." These premium cold-rolled stainless steel strips—extensively used in automotive moldings and telecommunications enclosures—are engineered to help manufacturers eliminate post-processing steps such as polishing and painting, while signifi...

MILANO--(BUSINESS WIRE)--Bending Spoons S.p.A. ("Bending Spoons"), azienda leader nel settore tecnologico, annuncia oggi il prezzo della propria offerta pubblica iniziale ("IPO"), pari a $29,00 per azione. Vengono offerte complessivamente 57.971.015 azioni ordinarie, di cui 34.398.640 offerte da Bending Spoons e 23.572.375 offerte da alcuni azionisti venditori (gli "Azionisti Venditori"). Bending Spoons non riceverà alcun provento dalla vendita di azioni da parte degli Azionisti Venditori. Si p...

MILAN--(BUSINESS WIRE)--Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Sharehold...